Aranda, E. http://orcid.org/0000-0002-5471-2842
Polo, E.
Camps, C.
Carrato, A.
Díaz-Rubio, E.
Guillem, V.
López, R.
Antón, A.
Funding for this research was provided by:
Bayer Hispania SL
Article History
Received: 11 December 2019
Accepted: 19 December 2019
First Online: 23 January 2020
Compliance with ethical standards
:
: EA has done speakers bureau, consulting or advisory roles for Amgen, Bayer, BMS, Celgene, Lilly, Merck, MSD, Pfizer, Roche, Sanofi and Servier, and has received travel accommodation expenses from Merck, Roche and Amgen. EP is advisory board member for Roche, Amgen, Merck, Ipsen, Bayer, Novartis and Pierre Fabre. CC is advisory board member for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, MSD, Roche, Bayer, Angellini; he has received research funding from AstraZeneca and Bristol-Myers Squibb, and speaker honoraria from AstraZeneca, Roche, MSD, Pfizer, Bristol-Myers Squibb and Takeda. AC has received advisory honorarium from Roche, Bayer, Merck, Celgene, Shire, Servier and MSD; he has received travel grants from BMS, Merck and Celgene. ED-R has a consulting or advisory role for Amgen, Bayer, Genomica, Servier, Merck Serono and MSD. VG has received speaker honorarium from Janssen, Astellas, BMS, MSD, Novartis, Pfizer and Roche; he has received research grants to institution from BMS, Roche and Janssen; he has received consulting honorarium from Astellas, and advisory honorarium from BMS, Janssen, Astellas, Roche, Boehringer, MSD and Merck; he has received travel grants from BMS, MSD, Roche, and Janssen. RL has no conflict of interest. AA is advisory board member for Bayer Hispania.
: The study was approved by a clinical research ethics committee.
: Informed consent was obtained from all individual participants included in the study.